The ICT-107 phase 3 registrational trial is open for enrollment in the US with additional sites anticipated to open in Canada and Europe in the coming weeks and months.
About the CBTC
The Canadian Brain Tumour Consortium (CBTC) creates value for its members, the industry and various cooperative groups by existing as a national investigator network of over 100 brain tumour specialists and researchers treating both pediatric and adult patients with brain tumour. The goal of the CBTC is to develop and promote multi-centre brain tumour research projects in Canada. The CBTC was established in 1998 and became a non-profit corporation in 1999. A professional, business-like approach enables the CBTC to partner effectively with industry to evaluate and execute clinical trials of promising new agents in a timely and cost-effective manner. By drawing together experts from across the country along with large patient pools, the CBTC can carry out large-scale, independent research studies not easily conquered by any single centre. For more information, please visit: http://www.cbtc.ca/index.htm.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient enrollment. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements, including statements regarding the development and commercialization of ICT-107, initiation of a phase 3 study of ICT-107 and the potential to accelerate the study through the relationship with the CBTC, the advancement of the ICT-121 phase 1 trial, the development of our preclinical Stem-to-T-cell program and our ability to achieve our other clinical, operational and financial goals. These statements are based on ImmunoCellular's current expectations and involve significant risks and uncertainties, including those described under the heading "Risk Factors" in ImmunoCellular's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as required by law, ImmunoCellular undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-establishes-agreement-with-the-canadian-brain-tumour-consortium-for-ict-107-phase-3-registrational-trial-in-glioblastoma-300191524.html
SOURCE ImmunoCellular Therapeutics, Ltd.